BR112022023722A2 - Processo para preparar um agonista dual de glp-1/glucagon - Google Patents

Processo para preparar um agonista dual de glp-1/glucagon

Info

Publication number
BR112022023722A2
BR112022023722A2 BR112022023722A BR112022023722A BR112022023722A2 BR 112022023722 A2 BR112022023722 A2 BR 112022023722A2 BR 112022023722 A BR112022023722 A BR 112022023722A BR 112022023722 A BR112022023722 A BR 112022023722A BR 112022023722 A2 BR112022023722 A2 BR 112022023722A2
Authority
BR
Brazil
Prior art keywords
glp
preparing
dual agonist
glucagon
glucagon dual
Prior art date
Application number
BR112022023722A
Other languages
English (en)
Inventor
Edward Kobierski Michael
Eugene Kopach Michael
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112022023722A2 publication Critical patent/BR112022023722A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

PROCESSO PARA PREPARAR UM AGONISTA DUAL DE GLP-1/GLUCAGON. A presente invenção refere-se a processos e compostos para a preparação de glucagon e compostos coagonistas de GLP-1 que são úteis no tratamento de diabetes tipo 2, obesidade, doença da esteatose hepática não alcoólica (NAFLD) e/ou esteato-hepatite não alcoólica (NASH).
BR112022023722A 2020-06-12 2021-06-11 Processo para preparar um agonista dual de glp-1/glucagon BR112022023722A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063038363P 2020-06-12 2020-06-12
PCT/US2021/036914 WO2021252829A1 (en) 2020-06-12 2021-06-11 Process for preparing a glp-1/glucagon dual agonist

Publications (1)

Publication Number Publication Date
BR112022023722A2 true BR112022023722A2 (pt) 2022-12-20

Family

ID=76731121

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023722A BR112022023722A2 (pt) 2020-06-12 2021-06-11 Processo para preparar um agonista dual de glp-1/glucagon

Country Status (17)

Country Link
US (1) US20230220000A1 (pt)
EP (1) EP4165058A1 (pt)
JP (1) JP2023529200A (pt)
KR (1) KR20230021740A (pt)
CN (1) CN115943151A (pt)
AR (1) AR122579A1 (pt)
AU (1) AU2021286660A1 (pt)
BR (1) BR112022023722A2 (pt)
CA (1) CA3182429A1 (pt)
CL (1) CL2022003459A1 (pt)
CO (1) CO2022017726A2 (pt)
EC (1) ECSP22094067A (pt)
IL (1) IL298265A (pt)
MX (1) MX2022015577A (pt)
PE (1) PE20230776A1 (pt)
TW (1) TWI810586B (pt)
WO (1) WO2021252829A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202404996A (zh) 2022-04-04 2024-02-01 美商美國禮來大藥廠 製備glp-1/升糖素雙重促效劑之方法
WO2024077149A2 (en) 2022-10-05 2024-04-11 Eli Lilly And Company Peptides for incretin synthesis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CN106519015B (zh) * 2014-09-23 2020-04-17 深圳市图微安创科技开发有限公司 胃泌酸调节素类似物
AR104932A1 (es) * 2015-06-22 2017-08-23 Lilly Co Eli Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
CN109456401B (zh) * 2018-12-03 2019-06-25 成都诺和晟泰生物科技有限公司 一种索马鲁肽的合成方法
CN109369798B (zh) * 2018-12-25 2020-09-15 苏州天马医药集团天吉生物制药有限公司 一种合成索玛鲁肽的方法
CN111217901A (zh) * 2019-10-31 2020-06-02 成都圣诺生物制药有限公司 一种索马鲁肽的制备方法

Also Published As

Publication number Publication date
MX2022015577A (es) 2023-01-30
PE20230776A1 (es) 2023-05-09
KR20230021740A (ko) 2023-02-14
CN115943151A (zh) 2023-04-07
ECSP22094067A (es) 2023-01-31
AR122579A1 (es) 2022-09-21
JP2023529200A (ja) 2023-07-07
US20230220000A1 (en) 2023-07-13
TWI810586B (zh) 2023-08-01
CL2022003459A1 (es) 2023-06-16
IL298265A (en) 2023-01-01
EP4165058A1 (en) 2023-04-19
TW202214678A (zh) 2022-04-16
WO2021252829A1 (en) 2021-12-16
AU2021286660A1 (en) 2022-12-22
CO2022017726A2 (es) 2022-12-20
CA3182429A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
BR112021020335A2 (pt) Agonistas glp-1r e usos dos mesmos
BR112022023722A2 (pt) Processo para preparar um agonista dual de glp-1/glucagon
CO2018000078A2 (es) Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
EA202191432A1 (ru) Агонисты glp-1r и их применения
AR118965A1 (es) Combinaciones para el tratamiento de nash / nafld y enfermedades relacionadas
BRPI0717098B8 (pt) análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação
BR112017008160A8 (pt) Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição
BR112017019170A2 (pt) métodos para o tratamento de doença do fígado gorduroso não alcoólico e / ou lipodistrofia
BR112013021236A8 (pt) composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença
BRPI0923359B8 (pt) molécula de anticorpo anti-igf, método para a produção da mesma, molécula de dna, vetor de expressão, e composição farmacêutica e método in vitro para inibir a ligação do igf-1 e do igf-2 ao receptor de igf-1 e ao receptor de insulina ir-a
BRPI0606727A (pt) terapia de combinação para o tratamento de diabetes e condições relacionadas com ele e para o tratamento de condições melhoradas através de aumento no nìvel de glp-1 no sangue
CR11179A (es) Anticuerpos humanizados contra el globometro ab (20-42) y sus usos
BR112022019532A2 (pt) Conjugados de neodegrader
BR112022023834A2 (pt) Composto duplo-agonista para os receptores de glp-1 e gip e aplicação do mesmo
MX2022003251A (es) Anticuerpo contra gipr y su proteina de fusion con glp-1, y composicion farmaceutica y aplicacion de los mismos.
BR112022020643A2 (pt) Método de tratamento de esteato-hepatite não alcoólica
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
AU2021377248A9 (en) Dichlorophenol hsd17b13 inhibitors and uses thereof
BR112022024678A2 (pt) Agonista de receptor ss de hormônio de tireoide inovador
BR112022025005A2 (pt) Formação de imagem e terapia dirigidas por granzima b
AR059636A1 (es) Metodo y composicion para tratar la enfermedad pulmonar obstructiva cronica
BR112019006428A2 (pt) sal de metformina do elafibranor e composição compreendendo um princípio ativo por incluir um sal de metformina do elafibranor
BR112023019984A2 (pt) Composição para prevenir ou tratar doenças neurodegenerativas compreendendo compostos que induzem a expressão do gene antienvelhecimento klotho
BR112022000684A2 (pt) Monotosilato de umbralisibe, processo para preparar uma forma amorfa, forma amorfa de monotosilato de umbralisibe, composição farmacêutica, e, método de tratamento de doença
CL2022002980A1 (es) Conjugado de proteínas novedoso, y uso del mismo para prevenir o tratar esteatohepatitis no alcohólica, obesidad y diabetes